接受造血祖移植的血液肿瘤疾病患者心肌生物标志物的释放情况

Revista Uruguaya de Cardiología Pub Date : 2021-03-17 DOI:10.29277/cardio.38.1.2

Soledad Murguía, Federico Pagnussat, A. Simeone, Mariela Lujambio, Mónica Delorenzi, Federico Acquistapace, Lucia Florio, Federico Ferrando Castagnetto

{"title":"接受造血祖移植的血液肿瘤疾病患者心肌生物标志物的释放情况","authors":"Soledad Murguía, Federico Pagnussat, A. Simeone, Mariela Lujambio, Mónica Delorenzi, Federico Acquistapace, Lucia Florio, Federico Ferrando Castagnetto","doi":"10.29277/cardio.38.1.2","DOIUrl":null,"url":null,"abstract":": BNP release after HSCT is frequent (32% of our patients), reaching a maximum at one month, regard-less of LVEF. The subgroup of patients who received antimetabolites had a greater early release of BNP.","PeriodicalId":191575,"journal":{"name":"Revista Uruguaya de Cardiología","volume":"66 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Perfil de liberación de biomarcadores miocárdicos en pacientes con enfermedades hemato-oncológicas que reciben trasplante de progenitores hematopoyéticos\",\"authors\":\"Soledad Murguía, Federico Pagnussat, A. Simeone, Mariela Lujambio, Mónica Delorenzi, Federico Acquistapace, Lucia Florio, Federico Ferrando Castagnetto\",\"doi\":\"10.29277/cardio.38.1.2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\": BNP release after HSCT is frequent (32% of our patients), reaching a maximum at one month, regard-less of LVEF. The subgroup of patients who received antimetabolites had a greater early release of BNP.\",\"PeriodicalId\":191575,\"journal\":{\"name\":\"Revista Uruguaya de Cardiología\",\"volume\":\"66 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-03-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista Uruguaya de Cardiología\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.29277/cardio.38.1.2\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Uruguaya de Cardiología","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29277/cardio.38.1.2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

HSCT后BNP释放很常见(占我们患者的32%)，无论LVEF如何，在1个月时达到最大值。接受抗代谢物治疗的患者亚组有更大的BNP早期释放。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Perfil de liberación de biomarcadores miocárdicos en pacientes con enfermedades hemato-oncológicas que reciben trasplante de progenitores hematopoyéticos

: BNP release after HSCT is frequent (32% of our patients), reaching a maximum at one month, regard-less of LVEF. The subgroup of patients who received antimetabolites had a greater early release of BNP.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Revista Uruguaya de Cardiología

自引率

0.00%

发文量